<DOC>
	<DOCNO>NCT02142127</DOCNO>
	<brief_summary>Human mass-balance study radiolabelled study drug need evaluate amount drug recover time via different elimination route body , i.e. , whole blood , blood cell , plasma , urine , feces , expire air . The ideal case able demonstrate ( near ) complete recovery ( ≥95 % ) administer dose . A good understanding metabolic pathway study drug equally important . Mass-balance data , together metabolic profile excreta , use characterize biotransformation pathway drug help evaluate drug-drug interaction potential . To purpose , study , blood , urine , feces collect investigate metabolic profile GFT505 , plasma urine collect investigate non-radioactive pharmacokinetics GFT505 principle metabolite GFT1007 . Other metabolite investigate plasma urine accord radioactivity result . Non-radioactive pharmacokinetics GFT505 metabolites feces investigate accord radioactivity result .</brief_summary>
	<brief_title>Mass Balance Study 14C-labelled GFT505 Healthy Volunteers</brief_title>
	<detailed_description>This Phase I open-label , single oral dose single center study 14C-labelled GFT505 metabolites healthy subject . After overnight fast , subject administer one dose 14C-labelled GFT505 contain equivalent 120 mg compound 240 mL non-carbonated water . The total amount administer radiocarbon 1.63-1.81 megaBecquerel ( MBq ) ( 44.1-48.8 μCi ) . Blood , urine , feces collect scheduled time interval administration radiolabelled study drug throughout confinement clinical center thereafter , need . Several sample expire carbon dioxide obtain 48 h administration radiolabelled study drug . Radiocarbon assay available sample ( whole blood , plasma , urine , feces , expire air ) liquid scintillation spectrometry . The metabolic profile GFT505 assay plasma , urine , feces . Non-radioactive pharmacokinetics GFT505 principle metabolite GFT1007 assay plasma urine . Other metabolite investigate plasma urine accord radioactivity result . Non-radioactive pharmacokinetics GFT505 metabolites feces investigate accord radioactivity result .</detailed_description>
	<criteria>Healthy Caucasian male age 55 65 year inclusive Body Mass Index ( BMI ) ≥ 18 ≤ 30 kg/m² Fitzpatrick skin type &lt; 4 No clinically relevant abnormality hematology clinical chemistry parameter , blood pressure ( BP ) heart rate ( HR ) ( supine ) , ECG result History presence hepatic , renal , respiratory , cardiovascular , neurologic , gastrointestinal , endocrine , immunologic , musculoskeletal , hematologic disorder capable alter absorption , metabolism , elimination drug , capable constitute risk factor take study drug , judge investigator ; Creatinine Clearance calculate CockcroftGault formula le 60 mL/min ; History irregular bowel movement regular episode diarrhea , constipation ( less mean one bowel movement per day ) irritable bowel movement ; Planning become father donate sperm within 3 month administration study drug ; History presence drug addiction ( positive drug screen amphetamine , barbiturate , benzodiazepine , cannabinoids , cocaine , opiates ) excessive use alcohol ( daily intake exceed 2 units/day ) ; Current use nicotine containing product , i.e. , 5 cigarette equivalent/day inability stop use nicotine containing product confinement clinical center ; Large caffeine consumption ( daily average 6 cups coffee tea 1L caffeinecontaining beverage ) within last year ; Plasma level ALT , AST , alkaline phosphatase ( ALP ) ≥1.5 x upper limit laboratory normal range ( ULN ) ; Blood donation loss significant amount blood within 12 week prior dose ; Inability understand constraint full urine stool collection inability collect urine ; Use drug treatment could affect outcome study 14 day administration radiolabelled study drug ( 2 month enzymeinducing drug ) 5 time halflife medication , anticipate use concomitant therapy ( except paracetamol ) study ; Exposure ionize radiation ( except routine dental radiography radiography extremity ) , include participation study radiolabelled compound , exposure radioisotope within one year prior entry present study ; Participation another clinical study within 12 week prior entry present study .</criteria>
	<gender>Male</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>GFT505</keyword>
	<keyword>Mass balance</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Metabolites</keyword>
	<keyword>Healthy subject</keyword>
	<keyword>Healthy male volunteer</keyword>
</DOC>